All Stories

  1. Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder
  2. Schizophrenia, Alcohol Use Disorder, and Stimulant Use Disorder
  3. Adolescent Suicidality and Depression, Premenstrual Dysphoric Disorder, and Safety Issues Related to Ketamine and Esketamine Treatment
  4. Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder
  5. Psychiatric Genetics and Assessing Telehealth Prescribing of Controlled Substances
  6. Adolescent Substance Use and Suicidal Behavior, Internet Overuse, and Shared Genetics Between Problematic Alcohol Use and Other Psychiatric Comorbidities
  7. Depression, Inflammation, and Postpartum Psychosis
  8. Diverse Treatment Strategies and the Valuable Work That Brings Them Forward
  9. Psychotic Disorders and Schizophrenia: Treatment, Risk, Brain Alterations, and Mechanisms
  10. New Developments in the Treatment of Depression, OCD, and Schizophrenia
  11. Tobacco, Alcohol, Heroin, Binge Eating, and Behavioral Addictions
  12. Homelessness, Discrimination, PTSD, Autism, and the Amygdala
  13. Substance Use Disorders
  14. Schizophrenia Spectrum Disorders and Psychosis
  15. Depression: Factors Contributing to Risk and Therapeutic Insights
  16. PTSD, Phobias, Suicide Attempts, and Psychiatric Vulnerabilities
  17. Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems
  18. Advances in Understanding Schizophrenia, ADHD, and ASD
  19. Psychopathology in Youth: Treatment, Parenting, and Intergenerational Transmission
  20. New Insights into Treatments Across the Lifespan
  21. New Developments in Understanding and Treating Opiate and Cannabis Use Disorders
  22. Improving Clinical Outcomes and Informing New Interventions
  23. Adversity and Resilience, Postpartum Depression, Suicide, and Racial/Ethnic Disparities
  24. Substance Use Disorders Are Psychiatric Disorders: Response to Balasanova
  25. Gene expression in the primate orbitofrontal cortex related to anxious temperament
  26. New Insights Into Psychotic Disorders
  27. Stress, Heritability, and Genetic Factors Influencing Depression, PTSD, and Suicidal Behavior
  28. From Postmortem Molecular Studies to Social Determinants of Health Relevant to Racial and Ethnic Disparities
  29. Focusing on Substance Use Disorders, Opioids, and Craving
  30. Treatment Issues Related to the Use of Psychedelics, Trichotillomania, Social Anxiety Disorder, Schizophrenia, and Opioid Use Disorder
  31. Insights From Genetic, Neuroimaging, and Behavioral Neuroscience Studies
  32. Insights and Advances Into Treatments for Major Depression
  33. Race-Related Disparities in Childhood Adversity, Trauma, and Stress-Related Psychopathology
  34. Childhood- and Neurodevelopment-Related Psychiatric Disorders
  35. New Therapeutic Approaches Involving Psychopharmacology, Digital Technology, and fMRI Neurofeedback
  36. Polygenic Risk Scores and Genetics in Psychiatry
  37. Opioid Use Disorder, Cannabis Use Disorder, and a Mindfulness Intervention Affecting Pain-Related Neural Substrates
  38. Combining Molecular and Neuroimaging Measures to Understand Psychopathology and Inform New Treatment Development
  39. The American Journal of Psychiatry’s Efforts Toward Eliminating Racism, Social Injustice, Health Care Inequities, and Publication Biases
  40. Neurodevelopmental and Neurodegenerative Illnesses: Autism, Fragile X Syndrome, Parkinson’s Disease, and Dementia
  41. Neuroscientific Advances Supporting New Treatments for Major Depression
  42. Structural Racism and the Imperative to Eliminate Mental Health Disparities
  43. From the Early Emergence of Psychiatry to Stem Cells and Neural Organoids
  44. Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia
  45. Insights Into the Genomic Underpinnings of Psychopathology
  46. Spanning Treatment Modalities: Psychotherapy, Psychopharmacology, and Neuromodulation
  47. Alcohol and Cannabis Use Disorders
  48. New Insights Into Major Depression and the Treatment of Bipolar Depression
  49. Adversity, Trauma, Suicide, and Alzheimer’s Disease
  50. Depression and Schizophrenia: Sleep, Medical Risk Factors, Biomarkers, and Treatment
  51. Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities
  52. Understanding the Value and Limitations of MRI Neuroimaging in Psychiatry
  53. Impacts of Structural Racism, Socioeconomic Deprivation, and Stigmatization on Mental Health
  54. COVID-19 and Stress-Related Disorders
  55. Scientific Advances Supporting New and Improved Treatment Strategies in Psychiatry
  56. Anxiety, Depression, and Suicide in Youth
  57. Improving Treatment Outcomes Includes Increasing the Diversity of the Psychiatric Workforce
  58. Trauma, Resilience, Anxiety Disorders, and PTSD
  59. Genes, Cells, and Neural Circuits Relevant to OCD and Autism Spectrum Disorder
  60. Molecules and Circuits Implicated in Schizophrenia Provide Leads for Novel Treatments
  61. Substance Use Disorders and Addiction: Mechanisms, Trends, and Treatment Implications
  62. Insights Into Suicide and Depression
  63. Childhood and Adolescent Neurodevelopmental Disorders
  64. The American Journal of Psychiatry’s Commitment to Combat Racism, Social Injustice, and Health Care Inequities
  65. Advances in Understanding and Treating Mood Disorders
  66. COVID-19, Substance Use, Anorexia Nervosa, 22q11.2 Deletion Syndrome, and Stress
  67. New Findings Related to Cognition, Intellectual Disability, Dementia, and Autism
  68. The Critical Relationship Between Anxiety and Depression
  69. Psychotic Experiences, Cognitive Decline, and Genetic Vulnerabilities in Relation to Developing Psychotic Disorders
  70. Novel Insights Into Pathological Anxiety and Anxiety-Related Disorders
  71. Treating Substance Use Disorders, Binge Eating, and Depression, and Identifying Factors Underlying Psychosis Risk
  72. Early-Life Environmental Factors Impacting the Development of Psychopathology
  73. Prefrontal Cortical and Limbic Circuit Alterations in Psychopathology
  74. Developing Innovative and Novel Treatment Strategies
  75. Gaining Ground on Schizophrenia: Conceptualizing How to Use Neuroimaging and Genomics in Its Diagnosis and Treatment
  76. Integrating Clinical Psychiatry With Behavioral Neuroscience: Reflections and a Call for Papers
  77. Psychiatric Genetics: Scientific Advances and Clinical Challenges
  78. Using Neuroimaging to Characterize Brain Alterations Associated With Psychopathology
  79. Developing Novel Psychopharmacological Strategies and Therapeutics
  80. New Insights Into the Mechanisms of Ketamine’s Antidepressant Effects: Understanding the Role of VEGF in Mediating Plasticity Processes
  81. Improving the Lives of Patients With Major Depression by Focusing on New Treatment Approaches
  82. Optimizing the Efficacy of Psychotherapy, Cognitive Training, and Internet Interventions
  83. Altered Uncinate Fasciculus Microstructure in Childhood Anxiety Disorders in Boys But Not Girls
  84. New Insights Highlighting Neurodevelopmental Issues That Predispose to Childhood and Adolescent Psychopathology
  85. New Findings Relevant to Substance Use Disorders
  86. An Introduction and Vision
  87. Corticotropin-Releasing Hormone Binding Protein: Stress, Psychopathology, and Antidepressant Treatment Response